AC
ARNA

Ascend Capital’s Arena Pharmaceuticals Inc ARNA Stock Holding History

Ascend Capital’s Portfolio ARNA Stock Details ARNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-114,423
Closed -$1.93M – 208
2017
Q2 		$1.93M Buy
114,423
+13,528
+13% +$186K 0.09% 134
2017
Q1 		$1.47M Sell
100,895
-81,605
-45% -$1.21M 0.07% 130
2016
Q4 		$2.59M Buy
+182,500
New +$2.83M 0.13% 118
2016
Q1 		– Sell
-82,214
Closed -$1.56M – 161
2015
Q4 		$1.56M Buy
+82,214
New +$1.68M 0.05% 132

Other funds holding ARNA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ascend Capital's ARNA Position: Q3 2017 in Review

Ascend Capital sold out of Arena Pharmaceuticals Inc (ARNA) in Q3 2017, closing a stake of 114,423 shares — an estimated $1.93M sold.

Ascend Capital first reported a position in ARNA in Q4 2015 and held it in 4 quarters. The position peaked at $2.59M in Q4 2016. 119 funds tracked by Wall St. Rank hold ARNA as of Q3 2017.

  • Ascend Capital reported no remaining Arena Pharmaceuticals Inc position as of Q3 2017 after selling out during the quarter.
  • Ascend Capital sold 114,423 Arena Pharmaceuticals Inc shares in Q3 2017, an estimated $1.93M.
  • Ascend Capital first reported a position in Arena Pharmaceuticals Inc in Q4 2015 and held it in 4 quarters.
  • Ascend Capital's Arena Pharmaceuticals Inc position peaked at $2.59M in Q4 2016.
  • 119 funds tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q3 2017.

Based on Ascend Capital's 13F filing for Q3 2017, filed 13 Nov 2017.